What is Relay Therapeutics, Inc.'s D&A?

Relay Therapeutics, Inc. (RLAY) reported D&A of $504K in Q1 2026.

How has Relay Therapeutics, Inc.'s D&A changed year-over-year?

Relay Therapeutics, Inc.'s D&A decreased by 58.3% year-over-year, from $1.21M to $504K.

What is the long-term trend for Relay Therapeutics, Inc.'s D&A?

Over 4 years (2021 to 2025), Relay Therapeutics, Inc.'s D&A has grown at a -2.4% compound annual growth rate (CAGR), from $3.93M to $3.56M.

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

Relay Therapeutics, Inc. RLAY D&A

D&A at other companies

CelcuityCELC

$47K+27.0%

Revolution Medicines, Inc.RVMD

$2.35M+38.7%

Ligand PharmaceuticalsLGND

$8.22M-6.3%

Cogent Biosciences, Inc.COGT

$626K-2.2%

Tango TherapeuticsTNGX

$463K-25.6%

LQD

Liquidia CorporationLQDA

$497K+10.2%

Other financials

Income statement

See full

Revenue$3.0M-60.9%

Operating income-$78.6M+7.4%

Net income-$73.3M+4.9%

EPS (diluted)-$0.41+10.9%

Balance sheet

See full

Cash & equivalents$204.6M+119%

Total debt$31.6M-33.1%

Total equity$642.2M-10.9%

Total assets$699.6M-12.5%

Cash flow

See full

Operating cash flow-$51.1M+30.2%

CapEx$1.0K—

Free cash flow-$44.9M+22.5%

Valuation

See full

Market cap$3.46B+300%

Enterprise value$3.29B+304%

P/S324.1×+212×

Profitability

See full

Operating margin-2,776.6%-820pp

Net margin-2,554.1%-745pp

FCF margin-1,536%-429pp

Returns & leverage

See full

Return on equity-40%-4.3pp

Debt / equity0×0.0×

Current ratio22.1×+2.2×

Where this comes from

Reported directly by Relay Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The official record: Relay Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Relay Therapeutics, Inc.'s d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Relay Therapeutics, Inc.'s D&A?: Relay Therapeutics, Inc. (RLAY) reported D&A of $504K in Q1 2026.
How has Relay Therapeutics, Inc.'s D&A changed year-over-year?: Relay Therapeutics, Inc.'s D&A decreased by 58.3% year-over-year, from $1.21M to $504K.
What is the long-term trend for Relay Therapeutics, Inc.'s D&A?: Over 4 years (2021 to 2025), Relay Therapeutics, Inc.'s D&A has grown at a -2.4% compound annual growth rate (CAGR), from $3.93M to $3.56M.
What does D&A mean?: Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.